Skip to main content

MoneyWorks4Me

Glenmark Pharmaceuticals informs about press release

17 Apr 2018 Evaluate

Glenmark Pharmaceuticals has informed about press release titled ‘Glenmark Pharmaceuticals Announces Initiation of a Phase 2b Trial of GBR 830, a First-in-Class, Investigational, Anti-OX40 Monoclonal Antibody for the Treatment of Moderate-to-Severe Atopic Dermatitis’.

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
Sun Pharma. Inds. 1795.10
Dr. Reddys Labs. 1368.95
Cipla 1394.45
Lupin 2014.45
Zydus Lifesciences 1257.10
View more..